borderline significantP = .06
By the 12-month follow-up, physical functioning scores in the 2 groups appeared to converge, though the difference remained borderline significant (ratio, 0.9; P = .06).
By the 12-month follow-up, physical functioning scores in the 2 groups appeared to converge, though the difference remained borderline significant (ratio, 0.9; P = .06).
The total severity score was higher in the immunocompromised than in the immunocompetent group at 1 month (median, 7 vs 4.74, respectively; P = .58) and at 6 months (5.75 vs 0; P = .11), corresponding with the greater number of symptoms in the immunocompromised group, though this difference did not reach statistical significance.